Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia.

Content Provider	Europe PMC
Author	Li, Jing Haase, Volker H. Hao, Chuan-Ming
Copyright Year	2022
Abstract	Background Anemia is a common complication of chronic kidney disease. The hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the treatment of renal anemia. Summary Clinical trials have consistently shown that HIF-PHIs can effectively increase hemoglobin in both the dialysis population and the nondialysis population. The effects of HIF-PHIs in treating renal anemia include promoting endogenous erythropoietin production and facilitating iron mobilization. Several studies suggest that the erythropoiesis effect of roxadustat is less affected by inflammation. Careful monitoring of thromboembolic events and tumor before and during HIF-PHI treatment is necessary. Key Messages HIF-PHIs are effective in correcting renal anemia. The long-term safety of HIF-PHIs needs to be further studied.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9900466&blobtype=pdf
Page Count	11
ISSN	22969381
Volume Number	9
DOI	10.1159/000527835
PubMed Central reference number	PMC9900466
Issue Number	1
PubMed reference number	36756084
Journal	Kidney Diseases [Kidney Dis (Basel)]
e-ISSN	22969357
Language	English
Publisher	Karger Publishers
Publisher Date	2022-10-31
Publisher Place	Allschwilerstrasse 10, CH-4055 Basel, Switzerland
Access Restriction	Open
Rights License	This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel
Subject Keyword	Hypoxia-inducible factor Chronic kidney disease Anemia Iron
Content Type	Text
Resource Type	Article
Subject	Nephrology